Cargando…

Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial

BACKGROUND: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). RESULTS: HT(–) and RILA(high) were the two independent factors associated with impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourgier, Céline, Castan, Florence, Riou, Olivier, Nguyen, Tan-Dat, Peignaux, Karine, Lemanski, Claire, Lagrange, Jean-Léon, Kirova, Youlia, Lartigau, Eric, Belkacemi, Yazid, Rivera, Sofia, Noël, Georges, Clippe, Sébastien, Mornex, Françoise, Hennequin, Christophe, Gourgou, Sophie, Brengues, Muriel, Fenoglietto, Pascal, Ozsahin, Esat Mahmut, Azria, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884662/
https://www.ncbi.nlm.nih.gov/pubmed/29644007
http://dx.doi.org/10.18632/oncotarget.24606
_version_ 1783311860605386752
author Bourgier, Céline
Castan, Florence
Riou, Olivier
Nguyen, Tan-Dat
Peignaux, Karine
Lemanski, Claire
Lagrange, Jean-Léon
Kirova, Youlia
Lartigau, Eric
Belkacemi, Yazid
Rivera, Sofia
Noël, Georges
Clippe, Sébastien
Mornex, Françoise
Hennequin, Christophe
Gourgou, Sophie
Brengues, Muriel
Fenoglietto, Pascal
Ozsahin, Esat Mahmut
Azria, David
author_facet Bourgier, Céline
Castan, Florence
Riou, Olivier
Nguyen, Tan-Dat
Peignaux, Karine
Lemanski, Claire
Lagrange, Jean-Léon
Kirova, Youlia
Lartigau, Eric
Belkacemi, Yazid
Rivera, Sofia
Noël, Georges
Clippe, Sébastien
Mornex, Françoise
Hennequin, Christophe
Gourgou, Sophie
Brengues, Muriel
Fenoglietto, Pascal
Ozsahin, Esat Mahmut
Azria, David
author_sort Bourgier, Céline
collection PubMed
description BACKGROUND: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). RESULTS: HT(–) and RILA(high) were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILA(low) and HT(+) than in patients with RILA(high) and HT(–) (75.8% and 100%, respectively; p = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8–19.1]). Conversely, BFFS at 36 months was comparable in patients with RILA(high) and HT(+) and in patients with RILA(low) and HT(–) (89.8% and 93.5%, respectively; p = 0.39, hazard ratio 1.7 [95% CI 0.51–5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy). CONCLUSIONS: HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILA(high) and HT(–) presented an excellent BFFS at 36 months (100%). MATERIALS AND METHODS: Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT(+) and HT(–), respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILA(low); ≥12%: RILA(high)).
format Online
Article
Text
id pubmed-5884662
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58846622018-04-11 Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial Bourgier, Céline Castan, Florence Riou, Olivier Nguyen, Tan-Dat Peignaux, Karine Lemanski, Claire Lagrange, Jean-Léon Kirova, Youlia Lartigau, Eric Belkacemi, Yazid Rivera, Sofia Noël, Georges Clippe, Sébastien Mornex, Françoise Hennequin, Christophe Gourgou, Sophie Brengues, Muriel Fenoglietto, Pascal Ozsahin, Esat Mahmut Azria, David Oncotarget Research Paper BACKGROUND: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). RESULTS: HT(–) and RILA(high) were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILA(low) and HT(+) than in patients with RILA(high) and HT(–) (75.8% and 100%, respectively; p = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8–19.1]). Conversely, BFFS at 36 months was comparable in patients with RILA(high) and HT(+) and in patients with RILA(low) and HT(–) (89.8% and 93.5%, respectively; p = 0.39, hazard ratio 1.7 [95% CI 0.51–5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy). CONCLUSIONS: HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILA(high) and HT(–) presented an excellent BFFS at 36 months (100%). MATERIALS AND METHODS: Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT(+) and HT(–), respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILA(low); ≥12%: RILA(high)). Impact Journals LLC 2018-03-02 /pmc/articles/PMC5884662/ /pubmed/29644007 http://dx.doi.org/10.18632/oncotarget.24606 Text en Copyright: © 2018 Bourgier et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Bourgier, Céline
Castan, Florence
Riou, Olivier
Nguyen, Tan-Dat
Peignaux, Karine
Lemanski, Claire
Lagrange, Jean-Léon
Kirova, Youlia
Lartigau, Eric
Belkacemi, Yazid
Rivera, Sofia
Noël, Georges
Clippe, Sébastien
Mornex, Françoise
Hennequin, Christophe
Gourgou, Sophie
Brengues, Muriel
Fenoglietto, Pascal
Ozsahin, Esat Mahmut
Azria, David
Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
title Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
title_full Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
title_fullStr Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
title_full_unstemmed Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
title_short Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
title_sort impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective french trial
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884662/
https://www.ncbi.nlm.nih.gov/pubmed/29644007
http://dx.doi.org/10.18632/oncotarget.24606
work_keys_str_mv AT bourgierceline impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT castanflorence impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT riouolivier impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT nguyentandat impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT peignauxkarine impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT lemanskiclaire impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT lagrangejeanleon impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT kirovayoulia impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT lartigaueric impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT belkacemiyazid impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT riverasofia impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT noelgeorges impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT clippesebastien impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT mornexfrancoise impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT hennequinchristophe impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT gourgousophie impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT brenguesmuriel impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT fenogliettopascal impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT ozsahinesatmahmut impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial
AT azriadavid impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial